Mesoblast’s AGM Results: All Resolutions Passed on November 25, 2025

Tip Ranks
2025.11.26 11:33
portai
I'm PortAI, I can summarize articles.

Mesoblast Limited announced that all resolutions were passed at its Annual General Meeting on November 25, 2025. The resolutions included the adoption of the remuneration report, election and re-election of directors, and approval of options and convertible notes. This reflects strong shareholder support and is expected to positively impact the company's strategic direction. Despite financial challenges, Mesoblast shows potential for future growth. The current analyst rating for MESO stock is Hold with a $14.50 price target.

TipRanks Black Friday Sale

  • Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Mesoblast ( (MESO) ) has provided an announcement.

On November 25, 2025, Mesoblast Limited announced the results of its Annual General Meeting, where all proposed resolutions were passed by a poll. The resolutions included the adoption of the remuneration report, election and re-election of directors, approval of options for long-term and short-term incentives, and the approval of convertible notes and warrants. These outcomes reflect strong shareholder support and are likely to positively impact the company’s strategic direction and stakeholder confidence.

The most recent analyst rating on (MESO) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.

Spark’s Take on MESO Stock

According to Spark, TipRanks’ AI Analyst, MESO is a Neutral.

Mesoblast’s overall stock score is driven by financial challenges and bearish technical indicators. Despite strong revenue growth and positive earnings call highlights, the company’s profitability issues and negative valuation metrics weigh heavily on the score. The potential for future growth, as indicated in the earnings call, provides some optimism.

To see Spark’s full report on MESO stock, click here.

More about Mesoblast

Mesoblast Limited is a company based in Australia, primarily involved in the development of innovative cellular medicines. The company focuses on regenerative medicine and cell therapy products, targeting conditions such as cardiovascular diseases, inflammatory ailments, and immune-mediated diseases.

Average Trading Volume: 240,229

Technical Sentiment Signal: Buy

Current Market Cap: $1.93B

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer